Covalon Technologies Ltd. (COV.V)
CAD 2.35
(3.07%)
CAD 2.35
(3.07%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 14.36 Million CAD | 91.66% |
| 2022 | 7.49 Million CAD | -22.72% |
| 2021 | 9.69 Million CAD | -22.34% |
| 2020 | 12.48 Million CAD | -42.78% |
| 2019 | 21.82 Million CAD | 10.97% |
| 2018 | 19.66 Million CAD | -6.41% |
| 2017 | 21.01 Million CAD | 406.19% |
| 2016 | 4.15 Million CAD | -12.72% |
| 2015 | 4.75 Million CAD | -27.75% |
| 2014 | 6.58 Million CAD | 215.15% |
| 2013 | 2.08 Million CAD | 42.6% |
| 2012 | 1.46 Million CAD | 11.89% |
| 2011 | 1.3 Million CAD | -4.9% |
| 2010 | 1.37 Million CAD | 25.86% |
| 2009 | 1.09 Million CAD | -33.61% |
| 2008 | 1.64 Million CAD | 283.74% |
| 2007 | 429.26 Thousand CAD | 7.71% |
| 2006 | 398.52 Thousand CAD | 0.0% |
| 2005 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 2.66 Million CAD | -7.94% |
| 2024 Q2 | 5.12 Million CAD | 92.46% |
| 2024 Q3 | 5.24 Million CAD | 6.07% |
| 2023 Q1 | 3.69 Million CAD | 181.76% |
| 2023 Q4 | 2.89 Million CAD | -19.81% |
| 2023 Q2 | 4.17 Million CAD | 12.92% |
| 2023 FY | 14.36 Million CAD | 91.66% |
| 2023 Q3 | 3.6 Million CAD | -13.6% |
| 2022 Q4 | 1.31 Million CAD | -38.94% |
| 2022 Q3 | 2.14 Million CAD | 23.29% |
| 2022 FY | 7.49 Million CAD | -22.72% |
| 2022 Q1 | 2.29 Million CAD | 187.23% |
| 2022 Q2 | 1.74 Million CAD | -24.01% |
| 2021 Q4 | -2.62 Million CAD | -151.57% |
| 2021 Q1 | 3.58 Million CAD | 97.71% |
| 2021 FY | 9.69 Million CAD | -22.34% |
| 2021 Q2 | 3.64 Million CAD | 1.59% |
| 2021 Q3 | 5.09 Million CAD | 39.92% |
| 2020 Q4 | 1.81 Million CAD | -40.44% |
| 2020 Q3 | 3.04 Million CAD | 9.05% |
| 2020 FY | 12.48 Million CAD | -42.78% |
| 2020 Q2 | 2.79 Million CAD | -42.26% |
| 2020 Q1 | 4.83 Million CAD | 22.88% |
| 2019 Q2 | 9.24 Million CAD | 100.77% |
| 2019 FY | 21.82 Million CAD | 10.97% |
| 2019 Q1 | 4.6 Million CAD | 7.48% |
| 2019 Q3 | 4.03 Million CAD | -56.31% |
| 2019 Q4 | 3.93 Million CAD | -2.56% |
| 2018 Q2 | 4.33 Million CAD | -4.5% |
| 2018 Q3 | 6.5 Million CAD | 50.11% |
| 2018 FY | 19.66 Million CAD | -6.41% |
| 2018 Q1 | 4.53 Million CAD | -37.35% |
| 2018 Q4 | 4.28 Million CAD | -34.16% |
| 2017 Q4 | 7.24 Million CAD | 56.17% |
| 2017 FY | 21.01 Million CAD | 406.19% |
| 2017 Q1 | 4.46 Million CAD | 1075.91% |
| 2017 Q2 | 4.7 Million CAD | 5.36% |
| 2017 Q3 | 4.63 Million CAD | -1.3% |
| 2016 Q1 | 1.62 Million CAD | 30.57% |
| 2016 Q4 | 379.4 Thousand CAD | -77.27% |
| 2016 Q3 | 1.66 Million CAD | 246.48% |
| 2016 Q2 | 481.72 Thousand CAD | -70.29% |
| 2016 FY | 4.15 Million CAD | -12.72% |
| 2015 FY | 4.75 Million CAD | -27.75% |
| 2015 Q3 | 1.18 Million CAD | -18.94% |
| 2015 Q4 | 1.24 Million CAD | 4.61% |
| 2015 Q2 | 1.46 Million CAD | 69.71% |
| 2015 Q1 | 862.82 Thousand CAD | 139.74% |
| 2014 Q3 | 701.59 Thousand CAD | -49.32% |
| 2014 Q4 | 359.9 Thousand CAD | -48.7% |
| 2014 FY | 6.58 Million CAD | 215.15% |
| 2014 Q1 | 4.13 Million CAD | 476.85% |
| 2014 Q2 | 1.38 Million CAD | -66.54% |
| 2013 Q2 | 225.12 Thousand CAD | 3.27% |
| 2013 Q3 | 928.47 Thousand CAD | 312.42% |
| 2013 FY | 2.08 Million CAD | 42.6% |
| 2013 Q4 | 717.2 Thousand CAD | -22.75% |
| 2013 Q1 | 218 Thousand CAD | 238.22% |
| 2012 Q3 | 564.45 Thousand CAD | 12.56% |
| 2012 Q4 | 64.45 Thousand CAD | -88.58% |
| 2012 FY | 1.46 Million CAD | 11.89% |
| 2012 Q1 | 334.39 Thousand CAD | 43.04% |
| 2012 Q2 | 501.49 Thousand CAD | 49.97% |
| 2011 Q2 | 691.84 Thousand CAD | 127.95% |
| 2011 Q1 | 303.51 Thousand CAD | 199.97% |
| 2011 FY | 1.3 Million CAD | -4.9% |
| 2011 Q4 | 233.77 Thousand CAD | 192.38% |
| 2011 Q3 | 79.95 Thousand CAD | -88.44% |
| 2010 Q1 | 443.41 Thousand CAD | -71.46% |
| 2010 Q4 | 101.18 Thousand CAD | -76.43% |
| 2010 Q3 | 429.29 Thousand CAD | 6.63% |
| 2010 Q2 | 402.59 Thousand CAD | -9.21% |
| 2010 FY | 1.37 Million CAD | 25.86% |
| 2009 FY | 1.09 Million CAD | -33.61% |
| 2009 Q1 | -294.34 Thousand CAD | -119.55% |
| 2009 Q3 | -250.78 Thousand CAD | -1269.43% |
| 2009 Q2 | -18.31 Thousand CAD | 93.78% |
| 2009 Q4 | 1.55 Million CAD | 719.51% |
| 2008 Q1 | 268.92 Thousand CAD | 372.18% |
| 2008 FY | 1.64 Million CAD | 283.74% |
| 2008 Q3 | -16.05 Thousand CAD | -110.01% |
| 2008 Q2 | 160.41 Thousand CAD | -40.35% |
| 2008 Q4 | 1.5 Million CAD | 9479.25% |
| 2007 Q1 | 139 Thousand CAD | -5.26% |
| 2007 Q3 | 64.98 Thousand CAD | -61.39% |
| 2007 Q4 | 56.95 Thousand CAD | -12.36% |
| 2007 Q2 | 168.32 Thousand CAD | 21.1% |
| 2007 FY | 429.26 Thousand CAD | 7.71% |
| 2006 Q3 | 120.99 Thousand CAD | 88.09% |
| 2006 FY | 398.52 Thousand CAD | 0.0% |
| 2006 Q4 | 146.72 Thousand CAD | 21.26% |
| 2006 Q1 | 75.38 Thousand CAD | 0.0% |
| 2006 Q2 | 64.32 Thousand CAD | -14.67% |
| 2005 Q4 | - CAD | -100.0% |
| 2005 Q2 | 7334.00 CAD | 225.96% |
| 2005 FY | - CAD | 0.0% |
| 2005 Q1 | 2250.00 CAD | 0.0% |
| 2005 Q3 | 13.34 Thousand CAD | 81.99% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Arch Biopartners Inc. | -128.99 Thousand CAD | 11233.899% |
| Hemostemix Inc. | -223.00 CAD | 6440386.547% |
| Universal Ibogaine Inc. | 1.07 Million CAD | -1241.22% |
| Kane Biotech Inc. | 109.47 Thousand CAD | -13019.429% |
| MedMira Inc. | -434.91 Thousand CAD | 3402.248% |
| Marvel Biosciences Corp. | -887.51 Thousand CAD | 1718.206% |
| NervGen Pharma Corp. | -145 Thousand CAD | 10004.512% |
| XORTX Therapeutics Inc. | -188.54 Thousand CAD | 7717.275% |